Compare Ascendis Pharma A/S (ASND) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Flux Power Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Flux Power Holdings Inc trades at $0.74 (market cap $16.65M). The key difference: Ascendis Pharma A/S is far larger — about 1065.5× Flux Power Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FLUX | |
|---|---|---|
Market Cap | $17.74B | $16.65M |
Sector | Health | Utilities |
52-Week High | $277.18 | $6.66 |
52-Week Low | $163.32 | $0.73 |
Enterprise Value | $18.11B | $22.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FLUX trades at $0.7765, up 0.36% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $6.67 million in 2025, with revenue declining to $51 million in 2026, though it maintains a low P/S ratio of 0.29. Recent news highlights the launch of SkyEMS 3.0 AI software, aiming to boost operational efficiency for fleet customers.
Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and net margins. Investment appeal hinges on revenue stabilization and cost management, but high execution risk and cash flow volatility warrant caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
